# Boston Scientific Showcases Clinical and Economic Benefits of Endoscopy Products at Digestive Disease Week®

NATICK, Mass., May 1, 2014 / PRNewswire / -- Boston Scientific Corporation (NYSE: BSX) will present select abstracts and clinical data analyses pertaining to key issues in gastroenterology during Digestive Disease Week (DDW®) 2014, May 4-6 in Chicago. Data presentations will include the Boston Scientific SpyGlass Direct Visualization System, the Resolution Clip and the recently FDA cleared and CE marked Expect Slimline Needle for use in Endoscopic Ultrasound-Fine Needle Aspiration (EUS-FNA) procedures.

"The added validation provided through the data in these presentations speaks to Boston Scientific's expertise in bringing valuable, innovative products and services to healthcare professionals and patients alike," said David Pierce, president, Endoscopy, Boston Scientific. "As a long-time global leader in the diagnosis and treatment of gastrointestinal diseases, we continue to offer advanced solutions for patients through our ongoing cooperation with and guidance from healthcare practitioners."

Products including the SpyGlass Direct Visualization System, <u>WallFlex™ Stents</u>, the Resolution Clip, and the Advanix™ Pancreatic Stent (currently undergoing premarket review by FDA and not available for sale in the U.S.), will be available for demonstration at the Boston Scientific booth, #1138, throughout DDW. The company will also offer hands-on product demonstrations for the Expect Slimline Needle, featured in several posters at the conference. The Expect Slimline Needle collects tissue samples during EUS-FNA procedures to diagnose malignancies in organs adjacent to the gastrointestinal tract. This new product is now available globally.

For more information on Boston Scientific endoscopy products, click here.

The Boston Scientific DDW booth will also feature new areas dedicated to physician and patient education and reimbursement support. The company is also introducing an area dedicated to practice efficiency to highlight its new focus on applying Lean Business Practices to help customers eliminate waste and improve the quality of care.

# Schedule of Key Podium and Poster Presentations (partial listing)

Poster presentations are scheduled in the South Hall of McCormick Place from8:00 a.m. to 5:00 p.m. All clinical data results are under embargo until the start of each scientific presentation and 8:00 a.m. for poster presentations.

# Sunday, May 4

Diagnostic Utility of Single-User PerOral Cholangioscopy for Indeterminate Biliary Strictures in Sclerosing Cholangitis The poster examines the diagnostic utility of single-user peroral cholangioscopy in sclerosing cholangitis.

The findings will be displayed in a poster session in Session 8115 in South Hall Su1634.

### The Clinical and Financial Implications of Failed Hemostasis in Gastroduodenal Ulcer Bleeding

Dr. Shyam Varadarajulu will present on the evaluation of the clinical and cost implications of failed endoscopic hemostasis in patients with gastroduodenal ulcer bleeding. To date, no data have been available on this topic from the national perspective. Ann Roy, a member of the Boston Scientific Health Economics & Reimbursement team, was a contributor to and a co-author of this abstract. The findings will be discussed in a podium session from 2:45 p.m. to 3:00 p.m. during Session 3545 in Su3545 South Hall S404.

# Monday, May 5

# EUS-Guided Liver Biopsy Provides Diagnostic Samples with Quantitative Yields Superior to Percutaneous or Transjugular Routes

This poster reports on findings from a head-to-head comparison of the tissue yield of several liver biopsy methods, including EUS-FNA, and will be available in South Hall M 1401.

# A Multicenter, Prospective, Randomized Study on Endosonographic Fine Needle Aspiration of Pancreatic Cystic Lesions Using Standard and Nitinol Needles: Phase I Results

The poster will discuss preliminary results of the study, which is evaluating the clinical value of nitinol needles versus standard needles. The poster will be on display in South Hall Mo 1417.

#### **About DDW**

<u>Digestive Disease Week® (DDW)</u> is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 4-6, 2014, at McCormick Place, Chicago. The meeting showcases more than 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology.

#### **About Boston Scientific**

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit <a href="https://www.bostonscientific.com">www.bostonscientific.com</a> and connect on <a href="https://www.bostonscientific.com">Twitter</a> and <a href="https://www.bostonscientific.com">Facebook</a>.

### **Cautionary Statement Regarding Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, markets for our products, clinical trials and data, product performance and impact, and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – *Risk Factors* in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – *Risk Factors* in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

## **CONTACTS**

Media:
Nisha Deo
Corporate Affairs & Communications
Boston Scientific Corporation
508-652-5609 (office)
nisha.deo@bsci.com

Investors:
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
508-652-5345 (office)
investor relations@bsci.com

SOURCE Boston Scientific Corporation